neoadjuvant chemotherapy alone WILMINGTON, Del., March 31, 2025--(BUSINESS WIRE)--AstraZeneca’s IMFINZI ® (durvalumab) in combination with gemcitabine and cisplatin as neoadjuvant treatment ...

Immune-mediated adverse events (imAEs) were consistent with the known profile of IMFINZI, manageable and mostly low-grade. Severe and Fatal Immune-Mediated Adverse Reactions Important immune ...

4 IMFINZI is also approved in Brazil in this setting based on the NIAGARA results. Regulatory applications are currently under review in the EU, Japan and several other countries. Severe and Fatal ...

4 IMFINZI is also approved in Brazil in this setting based on the NIAGARA results. Regulatory applications are currently under review in the EU, Japan and several other countries. Severe and Fatal ...

Durvalumab plus gemcitabine and cisplatin significantly improved event free survival and overall survival compared with gemcitabine and cisplatin. The Food and Drug Administration (FDA) has ...

AstraZeneca has secured another expansion of its Imfinzi for use in cancer patients before and after surgery. This time, a groundbreaking FDA approval makes the PD-L1 inhibitor the first ...

The U.S. Food and Drug Administration (FDA) on Monday approved AstraZeneca Plc's (NASDAQ:AZN) Imfinzi (durvalumab) in combination with gemcitabine and cisplatin as neoadjuvant treatment ...

so patients have often progressed to more severe disease before treatment starts, when options are limited and prognosis is poor. The improvement in survival seen with Imfinzi is a notable ...

Treatment continues until disease progression, severe side effects, or completion of eight cycles after surgery. The FDA approved neoadjuvant Imfinzi, gemcitabine and cisplatin, followed by adjuvant ...